The financing was backed by Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital to support international growth and research programmes.
"We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research. Our groundbreaking patient cohorts give researchers access to unique data and insights, accelerating development and access to new therapies, while dramatically reducing the cost of finding, engaging and collecting prospective data from patients."
AXA Venture Partners led the Series A round with backing from Seedcamp to help accelerate product development and international growth.
"We’re delighted to be partnering with AVP. We work heavily in the finance sector and we’re proud to partner with a household financial services brand. AVP is a perfect partner for us to grow within other regulated domains and geographies with AVP’s global reach."
The Cambridge-based synthetic gene provider raised the capital from Mercia Ventures to expand operations and develop its DNA synthesis platform.
"We are delighted to have closed this latest round of funding with Mercia, which provides further validation of Camena’s approach. The ability to read, write and manipulate DNA is the foundation of the synthetic biology value chain, yet developments in DNA synthesis have not kept pace with DNA sequencing and editing capabilities. Camena’s gSynth platform is revolutionising the DNA synthesis market by unlocking access to genes and accelerating discovery pipelines. As the focus on sustainability and supply-chain security become more acute, Camena is leading the way with a green synthesis technology and is already well positioned to serve this burgeoning market. The invention of next-generation DNA sequencing technologies transformed our ability to ‘read’ DNA. Our goal is to enable our customers to ‘write’ DNA with the same confidence and ease."
The funding round was led by KOMPAS VC to support manufacturing expansion and further research and development.
"What makes Material Evolution different is that we don’t believe it will be one material that saves the world. We believe that to rapidly scale across the industry we need to have localised material sources. We have created a product that not only produces lower emissions but is also lower in cost and has a higher performance. There is no silver bullet solution, but we believe that by decentralising cement production and using previously inaccessible waste we can scale our solution on a global level and truly change the cement industry."
Atomico led the Series A round with participation from existing investors including Lakestar, Kindred, and Maersk Growth.
"For those operating warehouses, ensuring 100% fulfilment ‘in time, all the time’ is crucial to meeting the demands of the modern consumer. A critical component to achieving this is high stock accuracy, but staff shortages, manual processes, and the speed demanded by customers means that critical decisions across the supply chain are currently being taken blindly,"
